OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT

Detalles Bibliográficos
Autores principales: Dodick, D, Diener, HC, Turkel, C, DeGryse, R, Brin, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620253/
http://dx.doi.org/10.1186/1129-2377-14-S1-P197
_version_ 1782265560122261504
author Dodick, D
Diener, HC
Turkel, C
DeGryse, R
Brin, M
author_facet Dodick, D
Diener, HC
Turkel, C
DeGryse, R
Brin, M
author_sort Dodick, D
collection PubMed
description
format Online
Article
Text
id pubmed-3620253
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-36202532013-09-20 OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT Dodick, D Diener, HC Turkel, C DeGryse, R Brin, M J Headache Pain Poster Presentation Springer 2013 2013-02-21 /pmc/articles/PMC3620253/ http://dx.doi.org/10.1186/1129-2377-14-S1-P197 Text en Copyright ©2013 Dodick et al; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Presentation
Dodick, D
Diener, HC
Turkel, C
DeGryse, R
Brin, M
OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
title OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
title_full OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
title_fullStr OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
title_full_unstemmed OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
title_short OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
title_sort onabotulinumtoxina for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of preempt
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620253/
http://dx.doi.org/10.1186/1129-2377-14-S1-P197
work_keys_str_mv AT dodickd onabotulinumtoxinaforchronicmigrainetreatment75responderanalysisfromdoubleblindrandomizedplacebocontrolledphaseofpreempt
AT dienerhc onabotulinumtoxinaforchronicmigrainetreatment75responderanalysisfromdoubleblindrandomizedplacebocontrolledphaseofpreempt
AT turkelc onabotulinumtoxinaforchronicmigrainetreatment75responderanalysisfromdoubleblindrandomizedplacebocontrolledphaseofpreempt
AT degryser onabotulinumtoxinaforchronicmigrainetreatment75responderanalysisfromdoubleblindrandomizedplacebocontrolledphaseofpreempt
AT brinm onabotulinumtoxinaforchronicmigrainetreatment75responderanalysisfromdoubleblindrandomizedplacebocontrolledphaseofpreempt

Ejemplares similares